0001127602-24-007634.txt : 20240229
0001127602-24-007634.hdr.sgml : 20240229
20240229163700
ACCESSION NUMBER: 0001127602-24-007634
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klinger Shannon Thyme
CENTRAL INDEX KEY: 0001866132
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 24704453
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
STREET 2: SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-02-27
0001682852
Moderna, Inc.
MRNA
0001866132
Klinger Shannon Thyme
200 TECHNOLOGY SQUARE
SUITE 300
CAMBRIDGE
MA
02139
1
Chief Legal Officer
0
Common Stock
7912
D
Stock Option (Right to Buy)
96.20
2024-02-27
4
A
0
23635
0
A
2025-02-27
2034-02-27
Common Stock
23635
23635
D
Restricted Stock Units
0
2024-02-27
4
A
0
12377
0
A
Common Stock
12377
12377
D
Stock Option (Right to Buy)
96.20
2024-02-27
4
A
0
60216
0
A
2025-02-27
2034-02-27
Common Stock
60216
60216
D
Restricted Stock Units
0
2024-02-27
4
A
0
10609
0
A
Common Stock
10609
10609
D
25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
50% of this option will vest and become exercisable on February 27, 2026 and the remaining 50% will vest and become exercisable on February 27, 2027, subject to the recipient's continued service.
25% of the shares subject to this restricted stock unit award will vest on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter.
/s/ Brian Sandstrom, as Attorney-in-Fact
2024-02-29